London, May 14, 2026, 12:11 BST
Reckitt Benckiser Group plc plans to outline its approach to digital science and generative AI in research and development this Thursday during an investor seminar. The company behind Dettol, Durex, Lysol and Nurofen isn’t unveiling any fresh financial or trading details, but said its “Reckitt Focus On: Digital Science” event kicks off at 15:00 BST and will be streamed. Investegate
The timing is what sets this session apart. In its April trading update, Reckitt posted a 0.6% rise in group like-for-like net revenue for the first quarter. Core Reckitt climbed 1.3%. Europe, though, fell 4.2%, while emerging markets jumped 7.6%. Like-for-like revenue takes out currency shifts and changes to the portfolio, aiming for a clearer picture of actual sales.
Reckitt shares edged up 1.04% to 4,564p at 11:55 BST, based on delayed figures from Barclays, after closing Wednesday at 4,518p. The stock was seeing a touch of buying ahead of the webcast.
Chief R&D Officer Angela Naef is set to lead the presentation, joined by Chief Financial Officer Shannon Eisenhardt, Chief Information and Digitisation Officer Nigel Richardson, and Bastien Parizot, who heads global business services and AI enterprise as senior vice president. Generative AI—software that can generate or analyze content from massive data sets—is being positioned by Reckitt as a catalyst for faster product development, paired with predictive science and internal data.
No earnings on the docket today—this one’s about credibility.
Reckitt faces pressure to prove digital tools bring more than just efficiency gains in the lab. Sales still hinge on what happens in the aisles, how much shoppers are willing to spend, and, on the health side, whether cold-and-flu bugs are making the rounds. In April, Chief Executive Kris Licht pointed to “very low seasonal incidence, weak categories in Europe and geopolitical disruption” as drags on Core Reckitt’s first quarter. Strip out seasonal OTC — those over-the-counter drugs not needing a prescription — and Core Reckitt managed a 3.1% gain. Reckitt
Capital returns still on the radar: Reckitt scooped up 208,000 ordinary shares on May 13, paying a volume-weighted average of 4,545.36p apiece. Those shares are headed for treasury, so they’re off the table for voting. The purchase leaves Reckitt with 638,967,290 voting rights in circulation.
Unilever isn’t letting up. The consumer goods giant said last month that artificial intelligence now lets its Beauty & Wellbeing teams process consumer insights 60% faster, chop the usual months-long concept-to-R&D-brief timeline down to days, and speed up formulation cycles. That’s the benchmark Reckitt’s digital science strategy will face, even if the two companies don’t always go head-to-head on every shelf.
The bigger threat could be coming from outside the laboratory. Back in April, Reuters highlighted mounting pressure on consumer goods firms as rising oil and energy prices bite. P&G, for one, has warned of an estimated $1 billion profit impact for fiscal 2027. “Oil seeps into everything,” Annex Wealth Management chief economist Brian Jacobsen told Reuters. Dan Coatsworth at AJ Bell noted that consumer staples names may try to pass on those extra costs—“but they might struggle.” Reuters
Reckitt is pushing a tight agenda here: speed up new-product pipelines, make launches more consistent, and squeeze enough productivity to keep margins intact if demand loses steam. The company’s already made it clear—don’t expect fresh trading updates this Thursday. Still, investors will be tuning in.
